Day 1 | Day 2
WEDNESDAY, 6 OCTOBER
13:00 Conference Registration
14:00 Chairperson’s Remarks
Stefan Barth, Ph.D., Head, Department of Pharmaceutical Product Development, Fraunhofer IME
14:05 Recombinant Human Multi-Domain Fusion Proteins
Stefan Barth, Ph.D., Head, Department of Pharmaceutical Product Development, Fraunhofer IME
Activated and dysregulated macrophages play a decisive role in the development of numerous inflammatory processes including progression of cancer. We have generated novel recombinant multi-domain immunotherapeutics by fusing different cytotoxic enzymes to a single chain fragment derived from the CD64-specific human antibody H22. Final aim is the application of tailor-made immunofusions not only considering the targeting moiety, but also the appropriate cytotoxic agent to specifically destroy diseased cells.
14:35 Antibodies-Conjugated Nanoparticles for Targeted Drug Delivery
Roland Kontermann, Ph.D., Professor, Biomedical Engineering, Institute of Cell Biology & Immunology, University of Stuttgart
Nanoparticles such as liposomes and polymers are versatile carrier systems for delivery of therapeutic molecules, e.g. chemotherapeutic drugs, siRNA and proteins. Conjugation of antibodies, antibody fragments or antibody-mimetic scaffolds to the particle surface allow for active delivery to target cells, e.g. for tumor therapy. Binding to target cells has been shown to promote intracellular uptake and can improve selectivity and therapeutic efficacy. Examples for the generation and application of various targeted nanoparticulate drug carriers will be presented.
15:05 Toxicity-Reducing Potential of Extracorporeal Affinity Adsorption Treatment in Combination with Empowered Antibodies in a Syngeneic Rat Tumor Model
Rune Nilsson, Ph.D., Associate Professor, Department of Oncology, Lund University
Extracorporeal affinity adsorption (ECAT) is a method that safely and efficiently reduces dose limiting toxicity associated with the administration of monoclonal antibodies conjugated with a cytotoxic payload. We have shown that in combination with ECAT higher doses of both radiolabeled (90Y and 177Lu) and drug-conjugated (auristatin) antibodies can be increased without increase of toxicity. During ECAT the circulating antibodies remaining in the blood is removed by in-line passage of the blood through an affinity adsorbent.
Sponsored by
15:35 Refreshment Break
16:00 Sponsored Presentation (Opportunities Available)
16:30 Bispecific and Bifunctional Antibodies for Therapeutic and Vaccine Applications
Mavanur R. Suresh, Ph.D., Associate Dean of Research, Faculty of Pharmacy and Pharmaceutical Sciences, University of Alberta, Canada
We have recently developed a universal dendritic cell targeting vector that can deliver any class of antigen for therapeutic and vaccine applications. This single vector can deliver proteins, peptides, DNA, gangliosides, carbohydrates and RNA.
18:30 – 21:00 BIOTECHNICA Night: Beer Hall, Full Dinner Reception, Live Band
(Please register to reserve your complimentary ticket ahead of time. No tickets will be available on-site.)